What is GEN inCode?
GEN inCode specializes in genomic testing aimed at the prevention, diagnosis, and treatment of cardiovascular disease. The company leverages both monogenic and polygenic risk assessments to deliver comprehensive risk evaluations, empowering physicians with data-driven insights for clinical decision-making. Their product suite, including CARDIO inCode-Score and LIPID inCode, is designed to refine patient treatment pathways and proactively address cardiovascular health challenges, a leading global health concern.
How much funding has GEN inCode raised?
GEN inCode has raised a total of $4.5M across 1 funding round:
Unspecified
$4.5M
Unspecified (2020): $4.5M with participation from Maven Capital Partners UK LLP
Key Investors in GEN inCode
Maven Capital Partners UK LLP
Maven Capital Partners UK LLP is a prominent venture capital firm known for its investments in various sectors. Their involvement suggests a strategic alignment with GEN inCode's growth objectives and potential for future expansion.
What's next for GEN inCode?
The substantial enterprise-level funding indicates GEN inCode is poised for significant scaling and market expansion. This strategic investment will likely fuel further research and development into advanced genomic testing technologies, enhance commercialization efforts, and potentially broaden the company's product portfolio. The focus on cardiovascular disease prevention positions GEN inCode to capture a growing market share in precision medicine and proactive healthcare solutions.
See full GEN inCode company page
